Meetings and Correspondence on Marketing and Advertising of Opioids

The following table includes correspondence and meetings with stakeholders in which views, opinions and information are relayed with the intent to inform the development of policies, guidance or regulations related to the restriction of marketing and advertising of opioids.

Responses to formal consultations and communication for the purposes of making simple enquiries or requests for information that do not have any relevance, in Health Canada's view, to the development of policies related to restricting the marketing and advertising of opioids are not included.

For more information on Health Canada's transparency policy when communicating with stakeholders, please see the Transparency of Stakeholder Communications for Marketing and Advertising of Opioids Initiatives page.

You can request copies of correspondence and documents shared as part of stakeholder meetings. Please note that any documents requested will be provided in the official language in which the entity submitted them to Health Canada.

The last update was done on March 26, 2019.

To view only the correspondence received in response to the Minister of Health's letter to manufacturers and distributors of opioids in Canada requesting that they respond to the opioid crisis by immediately suspending any and all marketing and advertising of opioids to health care professionals on a voluntary basis, please see the Response to the Call on the Pharmaceutical Industry to Voluntarily Suspend Marketing and Advertising of Opioids summary table.

For more information

• Transparency of Stakeholder Communications for Marketing and Advertising of Opioids Initiatives
• Response to the Call on the Pharmaceutical Industry to Voluntarily Suspend Marketing and Advertising of Opioids
• Restricting the Marketing and Advertising of Opioids
• Information and privacy notice for specific Health Products and Food Branch initiatives
• Privacy Act
• Access to Information Act